ERBB2 and non-small cell lung carcinoma: Also according to the AACR project GENIE consortium database, EGFR is mutated in 22.17%, ALK is mutated in 5.05%, BRAF is mutated in 5.34%, ERBB2 (HER2) is mutated in 4.12%, HRAS is mutated in 0.43%, KRAS is mutated in 29.7%, MET is mutated in 5.18%, NRAS is mutated in 1.14% and PIK3CA is mutated in 7.47% of non-small cell lung carcinoma patients.